Nuzenio

Samsung Bioepis Files

Samsung Bioepis Files news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

company 5 latest news signals 4 publisher sources 100/100 entity strength

Latest news

Samsung Bioepis lines up Opuviz syringe as European aflibercept rivals multiply - The Pharma LetterThe Pharma Letter · Mon, 10 Aug 2026 12:33:45 GMTSamsung Bioepis Files South Korea's First Approval for Biosimilar of Merck's $32.4 Billion Cancer Drug Keytruda - finance.biggo.comfinance.biggo.com · Mon, 10 Aug 2026 09:15:00 GMTSamsung Bioepis Files Korea’s First Keytruda Biosimilar Application - BusinesskoreaBusinesskorea · Mon, 10 Aug 2026 09:13:02 GMTSamsung Bioepis files first Korea application for Keytruda biosimilar - CHOSUNBIZ - ChosunbizChosunbiz · Mon, 10 Aug 2026 07:36:00 GMTSamsung Bioepis Launches OPUVIZ™ (Aflibercept) 40 mg/mL Pre-filled Syringe Across Europe - BusinesskoreaBusinesskorea · Mon, 10 Aug 2026 06:15:19 GMT

Timeline

Mon, 10 Aug 2026 12:33:45 GMTSamsung Bioepis lines up Opuviz syringe as European aflibercept rivals multiply - The Pharma Letter
Mon, 10 Aug 2026 09:15:00 GMTSamsung Bioepis Files South Korea's First Approval for Biosimilar of Merck's $32.4 Billion Cancer Drug Keytruda - finance.biggo.com
Mon, 10 Aug 2026 09:13:02 GMTSamsung Bioepis Files Korea’s First Keytruda Biosimilar Application - Businesskorea
Mon, 10 Aug 2026 07:36:00 GMTSamsung Bioepis files first Korea application for Keytruda biosimilar - CHOSUNBIZ - Chosunbiz
Mon, 10 Aug 2026 06:15:19 GMTSamsung Bioepis Launches OPUVIZ™ (Aflibercept) 40 mg/mL Pre-filled Syringe Across Europe - Businesskorea

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Samsung Bioepis Files.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

4 distinct publisher/source names are currently connected to this entity page.